Results 21 to 30 of about 351,938 (393)

Hepatic methotrexate-associated lymphoproliferative disorders identified by multiple liver tumors: a case report and review of the literature

Journal of Medical Case Reports, 2019
Background Methotrexate, an immunosuppressant, is widely used as the standard therapeutic drug for rheumatoid arthritis. With the increasing frequency of use of methotrexate, adverse effects of methotrexate have been reported, one of which is known as ...
Ryohei Ono, Tomohiro Kumagae, Haruki Uojima, Shinichi Teshima, Madoka Kudo, Izumi Kitagawa, Masaki Yoshizawa   +6 more
doaj   +1 more source

Reply: Methotrexate neurotoxicity due to drug interactions: an inadequate folinic acid effect [PDF]

, 2017
No abstract ...
Baird, Susan F., Forster, Victoria J., Halsey, Christina, Mair, Shona, Skinner, Roderick, van Delft, Frederik W.   +5 more
core   +1 more source

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

New England Journal of Medicine, 2000
BACKGROUND Neutralization of tumor necrosis factor a (TNF-alpha) for three to six months reduces the symptoms and signs of rheumatoid arthritis. However, the capacity of this approach to effect a more sustained benefit and its effect on joint damage are ...
eter, L. E., Ipsky, Esiree, M. M.F., Van Der, Eijde, Aniel, F. E., Urst, Erdinand, B. C, Reedveld, Oachim, K. R., Alden, Osef, S. S., Molen, Ichael, Eisman, Aul, Mery, regory, H. R., Arriman, Avinder, M. N., Aini   +28 more
semanticscholar   +1 more source

Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐Naive Patients With Moderately‐to‐Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Multicenter, Multi‐Country, Randomized, Double‐Blind, Active Comparator–Controlled Trial

Arthritis & Rheumatology, 2020
The SELECT‐EARLY trial was undertaken to study the effect of upadacitinib, an oral, reversible Janus kinase 1–selective inhibitor, as monotherapy in patients with predominantly early rheumatoid arthritis who were naive for or had limited exposure to ...
R. Vollenhoven, T. Takeuchi, A. Pangan, A. Friedman, M. Mohamed, Su Chen, M. Rischmueller, R. Blanco, R. Xavier, V. Strand   +9 more
semanticscholar   +1 more source

A comparison of vitamin A and leucovorin for the prevention of methotrexate-induced micronuclei production in rat bone marrow

Clinics, 2008
INTRODUCTION: Methotrexate, a folate antagonist, is a mainstay treatment for childhood acute lymphoblastic leukemia. It is also widely used in a low dose formulation to treat patients with rheumatoid arthritis.
Sampath Madhyastha, Latha V Prabhu, V Saralaya, Rajalakshmi Rai   +3 more
doaj   +1 more source

The pharmacogenetics of methotrexate [PDF]

Rheumatology, 2007
Methotrexate (MTX) is a cornerstone of therapy for rheumatoid arthritis. However, it is not universally effective and up to one-third of patients fail to respond to treatment, either because of inefficacy or adverse events, although at present it is not possible to predict therapy response accurately.
Samantha L. Hider, Wendy Thomson, Ian N. Bruce   +2 more
openaire   +2 more sources

Preventing and Managing Toxicities of High-Dose Methotrexate

The Oncologist, 2016
High-dose methotrexate (HDMTX), defined as a dose higher than 500 mg/m2, is used to treat a range of adult and childhood cancers. Although HDMTX is safely administered to most patients, it can cause significant toxicity, including acute kidney injury ...
Scott C. Howard, J. Mccormick, C. Pui, R. Buddington, Scott C. Howard, J. Mccormick, C. Pui, R. Buddington, R. Harvey   +8 more
semanticscholar   +1 more source

Methotrexate an Old Drug with New Tricks

International Journal of Molecular Sciences, 2019
Methotrexate (MTX) is the first line drug for the treatment of a number of rheumatic and non-rheumatic disorders. It is currently used as an anchor disease, modifying anti-rheumatic drug in the treatment of rheumatoid arthritis (RA).
Y. Bedoui, X. Guillot, Jimmy Selambarom, P. Guiraud, C. Giry, M. Jaffar-Bandjee, S. Ralandison, P. Gasque   +7 more
semanticscholar   +1 more source

Adverse Effects of Low-Dose Methotrexate

Annals of Internal Medicine, 2020
Background Low-dose methotrexate (LD-MTX) is the most commonly used drug for systemic rheumatic diseases worldwide and is the recommended first-line agent for rheumatoid arthritis.
D. Solomon, R. Glynn, E. Karlson, Fengxin Lu, Cassandra Corrigan, J. Colls, Chang Xu, Jean G Macfadyen, M. Barbhaiya, N. Berliner, P. Dellaripa, Brendan M. Everett, A. Pradhan, S. Hammond, M. Murray, Deepak A. Rao, S. Ritter, Anna E. Rutherford, J. Sparks, J. Stratton, Dong-Hyun Suh, S. Tedeschi, K. Vanni, N. Paynter, P. Ridker   +24 more
semanticscholar   +1 more source

EXACERBATION OF ANKYLOSING SPONDYLITIS AFTER LOW-DOSE METHOTREXATE THERAPY

Alʹmanah Kliničeskoj Mediciny, 2016
Background: Efficacy of methotrexate in ankylosing spondylitis (AS) is disputable. Nevertheless, methotrexate is still used for disease-modifying therapy of AS. Aim: To assess efficacy and safety of methotrexate in AS patients.
A. V. Orlov-Morozov
doaj   +1 more source